Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Inipharm
AddedFeb 17, 2024
UpdatedJun 18, 2026
Inipharm

Inipharm

Public

Inipharm, Inc., a leading biotechnology firm, innovating for a healthier future.

HQ
Seattle, WA, US
Founded
2018
Overview
Compare
Fundraising
Employees
Website

Inipharm, Inc. is a biotechnology company founded with the mission to discover and develop therapies for severe liver diseases. The company's core focus is on addressing highly unmet medical needs through scientifically validated approaches. Inipharm's lead program targets the genetically-defined enzyme HSD17B13, which is associated with significantly lower rates of liver disease in individuals with certain genetic variants. Their market focus includes patients suffering from severe liver conditions who have limited treatment options.

Notable figures affiliated with Inipharm include experienced leaders in biopharmaceutical development and research. The company has attracted significant investment from reputable biotech investors, enabling it to advance its innovative therapies. Key achievements include the development of a promising lead program targeting HSD17B13, which has shown potential in reducing liver disease rates. Overall, Inipharm's impact lies in its potential to transform the treatment landscape for severe liver diseases, offering hope to patients with few alternatives.

Inipharm - Similar Companies

InpharmD logo

InpharmD

inpharmd.com

Hepanova logo

Hepanova

hepanova.com

Avalyn Pharma logo

Avalyn Pharma

avalynpharma.com

Inception Sciences logo

Inception Sciences

PIN Pharma logo

PIN Pharma

pinpharma.com

Anji Pharmaceuticals logo

Anji Pharmaceuticals

Phoenicis logo

Phoenicis

pH Pharma logo

pH Pharma

ph-pharma.com

CinRx Pharma logo

CinRx Pharma

cinrx.com

IpiNovyx Bio logo

IpiNovyx Bio

Apic Bio logo

Apic Bio

Bluejay Therapeutics logo

Bluejay Therapeutics

bluejaytx.com

Intercept Pharmaceuticals logo

Intercept Pharmaceuticals

Visiox logo

Visiox

visioxpharma.com

Complexa logo

Complexa

Inipharm - Quick Facts

Who are Inipharm's competitors?

Companies similar to Inipharm include InpharmD, Hepanova, Avalyn Pharma and Inception Sciences.

When was Inipharm founded?

Inipharm was founded in 2018.

Where is Inipharm's headquarters located?

Inipharm's headquarters is located in Seattle, WA, US.

When was Inipharm's last funding round?

Inipharm's most recent funding round was for $35M (USD) in November 2020.

How much has Inipharm raised to-date?

As of Nov 11, 2020, Inipharm has raised a total of $35M (USD).

How many employees does Inipharm have?

Inipharm has 9 employees as of Feb 4, 2024.

Inipharm - Classification

Ownership
  • Public
Technology
  • Biotech
Geographic Exposure
  • Global
Revenue
  • Recurring
Customer
  • Enterprise
Main Product
  • Therapies
Tags
  • Healthtech
NAICS
  • 320000Manufacturing
  • 325400Pharmaceutical and Medicine Manufacturing
  • 325000Chemical Manufacturing
  • 325410Pharmaceutical and Medicine Manufacturing
  • 325412Pharmaceutical Preparation Manufacturing
SIC
  • 2800Chemicals And Allied Products
  • 2830Drugs
  • 2834Pharmaceutical Preparations